A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies
- PMID: 28511883
- DOI: 10.1016/j.eururo.2017.04.034
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies
Abstract
Background: Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma.
Objective: We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors.
Design, setting, and participants: A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed.
Outcome measurements and statistical analysis: IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis.
Results and limitation: Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing.
Conclusions: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality.
Patient summary: A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.
Keywords: Cribriform architecture; Genomic instability; Hypoxia; Intraductal carcinoma; Prognosis; SChLAP1.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Convergence of Genomic Instability and SChLAP1: Weathering the Storm of Intraductal Carcinoma of the Prostate.Eur Urol. 2017 Nov;72(5):675-676. doi: 10.1016/j.eururo.2017.05.015. Epub 2017 May 18. Eur Urol. 2017. PMID: 28528812 No abstract available.
Similar articles
-
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.BMC Cancer. 2018 Jan 2;18(1):8. doi: 10.1186/s12885-017-3976-z. BMC Cancer. 2018. PMID: 29295717 Free PMC article.
-
Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy.Urol Oncol. 2022 Jan;40(1):5.e1-5.e13. doi: 10.1016/j.urolonc.2021.08.013. Epub 2021 Sep 17. Urol Oncol. 2022. PMID: 34538726
-
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Lancet Oncol. 2014 Dec;15(13):1469-1480. doi: 10.1016/S1470-2045(14)71113-1. Epub 2014 Nov 17. Lancet Oncol. 2014. PMID: 25456366 Free PMC article.
-
Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.Int J Mol Sci. 2021 Dec 4;22(23):13125. doi: 10.3390/ijms222313125. Int J Mol Sci. 2021. PMID: 34884926 Free PMC article. Review.
-
Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.Eur Urol Oncol. 2018 May;1(1):21-28. doi: 10.1016/j.euo.2018.03.013. Epub 2018 May 15. Eur Urol Oncol. 2018. PMID: 31100224 Review.
Cited by
-
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17. Mol Cancer Res. 2019. PMID: 30333152 Free PMC article.
-
Current Understanding and Management of Intraductal Carcinoma of the Prostate.Curr Oncol Rep. 2021 Jul 16;23(9):110. doi: 10.1007/s11912-021-01090-2. Curr Oncol Rep. 2021. PMID: 34272624 Review.
-
Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations.Am J Cancer Res. 2021 Aug 15;11(8):3990-4001. eCollection 2021. Am J Cancer Res. 2021. PMID: 34522463 Free PMC article.
-
Bad neighbours: hypoxia and genomic instability in prostate cancer.Br J Radiol. 2020 Nov 1;93(1115):20200087. doi: 10.1259/bjr.20200087. Epub 2020 Jun 18. Br J Radiol. 2020. PMID: 32551913 Free PMC article. Review.
-
Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate.Cancers (Basel). 2021 Dec 13;13(24):6243. doi: 10.3390/cancers13246243. Cancers (Basel). 2021. PMID: 34944863 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical